Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:45PM CST
Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug application for buprenorphine HCl buccal film.
BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15)
Auxilium Pharmaceuticals Shares Up 69.2% Since SmarTrend's Buy Recommendation (AUXL)
Comtex SmarTrend(R) - Wed Dec 24, 9:35AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 4 months, Auxilium Pharmaceuticals has returned 69.20% as of today's recent price of $34.17.
AUXL: 34.40 (+0.18)
3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)
Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)
Sobi awarded CHMP's positive opinion for Xiapex for the treatment of Peyronie's disease
M2 - Tue Dec 23, 5:37AM CST
Healthcare company Swedish Orphan Biovitrum AB (Sobi) and partner Auxilium Pharmaceuticals on Monday jointly announced the receipt of positive opinion for Xiapex for treating adult men with Peyronie's disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.
AUXL: 34.40 (+0.18)
Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
PR Newswire - Mon Dec 22, 6:00AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
AUXL: 34.40 (+0.18)
Uptrend Call Working As Auxilium Pharmaceuticals Stock Rises 63.1% (AUXL)
Comtex SmarTrend(R) - Wed Dec 17, 9:06AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 63.06% as of today's recent price of $32.93.
AUXL: 34.40 (+0.18)
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 16, 10:26AM CST
Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, licensing agreements and strong performances.
MDVN: 99.23 (+1.23), OREX: 5.98 (+0.01), ENDP: 72.10 (+0.34), BMRN: 88.18 (+0.89), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15), MNKD: 5.68 (+0.18), CELG: 109.60 (+3.48)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Endo International's SEC form S-4 declared effective
M2 - Fri Dec 12, 7:01AM CST
Healthcare company Endo International (NasdaqGS:ENDP) (TSX:ENL.TO) said on Thursday that its registration statement on Form S-4 has been declared effective by the US Securities and Exchange Commission (SEC) in connection with its acquisition of Auxilium Pharmaceuticals.
ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18)
Auxilium sets special shareholders meeting
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 6:19AM CST
ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18)
Auxilium Announces Date for Special Meeting of Stockholders
PR Newswire - Thu Dec 11, 4:05PM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that it has scheduled a special meeting of its stockholders for 8:30 a.m. ET on Tuesday, January 27, 2015 to approve matters relating to the previously announced proposed merger with Endo International plc.
AUXL: 34.40 (+0.18)
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC
PR Newswire Europe - Thu Dec 11, 4:00PM CST
Endo International plc today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the company's Registration Statement on Form S-4. The Form S-4 registers with the SEC Endo's ordinary shares to be issued in connection with the pending acquisition of Auxilium Pharmaceuticals.
ENDP: 72.10 (+0.34), ENL.TO: 83.00 (+0.91), AUXL: 34.40 (+0.18)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 114.11 (+0.64), ENDP: 72.10 (+0.34), BDX: 139.90 (+1.44), MDT: 74.08 (+0.31), COV: 103.35 (+0.57), ITMN: 73.89 (-0.02), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), CBST: 100.29 (-0.09), CFN: 59.18 (+0.04), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), IDIX: 24.50 (+0.05), SYK: 96.00 (-0.61), NVS: 93.91 (+0.66)
Shares of AUXL Up 69.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 09, 4:45PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 69.00% as of today's recent price of $34.13.
AUXL: 34.40 (+0.18)
Critical Alerts For General Electric, Auxilium Pharmaceuticals, Canadian Solar, JP Morgan Chase and VoxelJet Released By InvestorsObserver
PR Newswire - Thu Dec 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GE, AUXL, CSIQ, JPM and VJET.
GE: 25.83 (-0.05), JPM: 62.48 (unch), VJET: 7.29 (-0.15), AUXL: 34.40 (+0.18), CSIQ: 22.82 (+0.21)